Nadine Kuhl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nadine Kuhl has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Cheol K. Chung
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
8 shared publications - David A. Thaisrivongs
Department of Process Research and Development
7 shared publications James Corry
Process Research and Development, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
5 shared publications- Justin A. Newman
Pharmaceutical Analysis & Digital Technologies, Merck & Company, Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
5 shared publications Reed T. Larson
Department of Process Research and Development
5 shared publicationsRichard Desmond
Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
5 shared publications
Latest Publications
- 30 October 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (45) , 12505-12511
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19
An enantioselective seven-step synthesis of MK-7845, an investigational protease inhibitor for the treatment of COVID-19 is described. Key features of the synthesis include the preparation of a chiral isonitrile intermediate utilizing an asymmetric ruthenium-catalyzed reductive amination reaction to set the key amine stereocenter; a highly enantioselective, biocatalytic oxidation reaction with a monoamine oxidase enzyme to furnish a bicyclic imine; and, finally, the union of these fragments via a diastereoselective three-component Joullié-Ugi coupling reaction en route to MK-7845.
- 30 October 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (45) , 12505-12511
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19
An enantioselective seven-step synthesis of MK-7845, an investigational protease inhibitor for the treatment of COVID-19 is described. Key features of the synthesis include the preparation of a chiral isonitrile intermediate utilizing an asymmetric ruthenium-catalyzed reductive amination reaction to set the key amine stereocenter; a highly enantioselective, biocatalytic oxidation reaction with a monoamine oxidase enzyme to furnish a bicyclic imine; and, finally, the union of these fragments via a diastereoselective three-component Joullié-Ugi coupling reaction en route to MK-7845.
- Open Access
- 23 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1538-1553
Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines
- 23 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1538-1553
Open AccessDrug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines
- 21 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1152-1167
Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control
- 21 March 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (4) , 1152-1167
Industrial Case Studies Demonstrating Applicability of ICH M7 Control Options 3 and 4 for Nitrosamine Control
- 20 January 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (2) , 401-410
Quality Control for Incoming Raw Materials Beyond Identity and Purity: Case Studies from Recent Merck API Manufacturing Processes
- 20 January 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (2) , 401-410
Quality Control for Incoming Raw Materials Beyond Identity and Purity: Case Studies from Recent Merck API Manufacturing Processes
- 30 May 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2309-2316
The First GMP Synthesis of MK-2118, a Small Molecule Agonist for Stimulator of Interferon Genes
- 30 May 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2309-2316
The First GMP Synthesis of MK-2118, a Small Molecule Agonist for Stimulator of Interferon Genes
- 24 October 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1965-1974
Manufacturing Process Development for the Biaryl Ether Fragment of Nemtabrutinib (MK-1026)
- 24 October 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (11) , 1965-1974
Manufacturing Process Development for the Biaryl Ether Fragment of Nemtabrutinib (MK-1026)